Drug intelligence / Profile preview

EP0015

Development stage: Preclinical
Lead developer: Ellipses Pharma
Modality: Small Molecules
Administration: Oral

Overview

EP0015 is a preclinical-stage small molecule therapeutic being developed by Cancer Research Horizons for the treatment of multiple cancer indications. The compound is designed to induce cell death in tumor cells, although its specific molecular target has not been publicly disclosed in primary pipeline documentation. It is currently part of the Cancer Research Horizons portfolio, which focuses on accelerating the transition of academic discoveries into new cancer treatments through industry partnerships and internal drug discovery efforts.

Beyond the preview

Go deeper on EP0015.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EP0015.

Explore the full profile